sector medic suppli devic
downgrad neutral
messag share standout perform within diabet
devic segment year vs russel strong underli
momentum smoother expect transit dash driven upsid
street number improv sentiment continu view well
posit competit differenti form factor uniqu pay go
busi model see risk/reward stock less attract given lofti
valuat ntm sale increas investor expect come strong
perform result downgrad share neutral buy
remov prior price target
continu see well posit within insulin pump market given
omnipod uniqu tubeless form factor pay go busi model
appeal payer fit direct believ diabet industri head
longer term compani transit pharmaci channel thu far smoother
expect dash launch provid opportun extract posit
price rather absorb price headwind shift
away dme channel combin solid underli volum trend pump
market broadli dynam give us confid abil sustain
top line growth next year
challeng believ outlook reflect stock
current level come year highlight prefer way play
diabet space larg part felt carri much lower investor expect
come impress perform
forward today share doubl back strong vs
russel yet consensu forecast sale
time sinc compani gave initi guidanc bulk
stock appreci driven instead multipl expans trade ntm sale
forecast one hand small-cap med-tech compani garner
double-digit revenu multipl rest name list
expect grow top line much faster rate base current consensu
outlook revers start year also trade
signific premium figur
expect continu enjoy solid momentum base busi
comp get tougher quarter particularli true intern
omnipod segment benefit particularli easi comparison driven
inventori buyback prior year period posit price impact
switch direct sale forc compani anniversari juli outlook
drug deliveri busi also expect weaken back half year
guidanc call sale grow neulasta
experi increas gener pressur result see upsid potenti
manag overal revenu guidanc think slowdown cc growth
like
adjust estim make small chang model reflect
recent convert note offer manag prior commentari regard gross
margin progress back half year expect adjust ep
previous top line model continu call total sale
longer term continu see revenu grower
page analyst certif import disclosur
page analyst certif import disclosur
develop insulin infus system peopl insulin-depend diabet
compani omnipod system novel dispos patch pump believ offer
varieti advantag tradit durabl insulin pump includ elimin
tube connect pump patient improv comfort increas conveni
attribut allow carv meaning posit insulin pump
market estim approach world-wide revenu last year
believ continu take share go forward driven recent competitor
exit market launch new dash mobil platform shift direct sale
europ label expans includ concentr insulin formul
estim could effect doubl omnipod address market open type
opportun take factor account see posit
sustain top line growth next year driven continu execut
steadi cadenc pipelin oper catalyst repres strong
fundament outlook see base case forecast fulli reflect
stock current level
valu primarili ev/sal basi use repres group small-
mid-cap med-tech name similar growth characterist comp base
guggenheim factset consensu estim group current trade
ntm sale well insulet multipl better opportun elsewher
within small- mid-cap med-tech group opinion downgrad share
buy neutral
upsid risk rate includ faster expect insulin pump adopt within
type type diabet segment better expect adopt dash drive
new patient add estim compani abil garner better
expect price shift pharmaci channel
downsid risk rate includ failur keep pace innov
competitor caus omnipod adopt fall short street expect
disrupt compani product suppli chain faster anticip
penetr neulasta biosimilar could neg impact drug deliveri
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
